Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A population pharmacokinetic-metabolism model for individualizing ciprofloxacin therapy in ophthalmology.

Therapeutic drug monitoring - 1 Aug 2004

Di Marco Marika Pasternyk, Chen John, Wainer Irving W, Ducharme Murray P

Abstract excerpt

The purpose of this study was to construct a population pharmacokinetic (PK) metabolism (MB) model to describe ciprofloxacin (C) concentrations in plasma and vitreous and aqueous humors in 26 patients. Ciprofloxacin was given as a 3-day oral prophylactic treatment to 26 patients before vitrectomy. Plasma, vitreous, and aqueous humor samples were collected from patients at different times on the day of surgery....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Administration, Topical

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anti-Infective Agents

Share to Chromatography, High Pressure Liquid

Share to Ciprofloxacin

Share to Cytochrome P-450 CYP1A2

Share to Models, Biological

Share to Time Factors

Source

Identifiers

PMID: 15257070
DOI: 10.1097/00007691-200408000-00010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

A population pharmacokinetic-metabolism model for individualizing ciprofloxacin therapy in ophthalmology.PMID 15257070Read ↗

Vancomycin Population Pharmacokinetic Models in Non- Critically Ill Adults Patients: a scoping reviewSemantic proximity Read ↗

Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.Semantic proximity Read ↗

Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.Semantic proximity Read ↗

Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance.Semantic proximity Read ↗

In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.Semantic proximity Read ↗

Semimechanistic pharmacokinetic-pharmacodynamic model with adaptation development for time-kill experiments of ciprofloxacin against Pseudomonas aeruginosa.Semantic proximity Read ↗

Individualizing amikacin regimens: accurate method to achieve therapeutic concentrations.Semantic proximity Read ↗

Pharmacokinetic/pharmacodynamic model-based combination therapy approach to target antibiotic resistant populations emerged from ciprofloxacin exposure.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.